Literature DB >> 10762668

Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice.

S Hao1, Y Avraham, R Mechoulam, E M Berry.   

Abstract

This investigation reports the possible role of the endocannabinoid anandamide on modulating the behavioral and neurochemical consequences of semi-starvation. We studied the effect of very low dose anandamide (0.001 mg/kg) administration on food intake, cognitive function and catecholaminergic and serotonergic pathways in two murine brain areas concerned with appetite (hypothalamus) and learning (hippocampus), and the peripheral corticosterone response to the stress of 40% diet restriction. Anandamide-treated mice consumed 44% more food (P<0.05) during 1 week of 2.5-h feeding each day. In the hypothalamus, there were significantly increased concentrations of norepinephrine (P<0.01), dopamine (P<0.05) and 5-hydroxytryptamine (5-HT) (P<0.001). In the hippocampus, anandamide increased significantly norepinephrine and dopamine, but decreased 5-HT (all at P<0.001). Diet restriction was accompanied in both areas by a significant decrease in all neurotransmitter concentrations that were partially restored by anandamide for dopamine and 5-HT, but not for norepinephrine. In animals on diet restriction, anandamide significantly improved impaired maze performance. Norepinephrine turnover and plasma corticosterone levels were also raised significantly by anandamide. The fact that low dose anandamide improved food intake, cognitive function and reversed some of the neurotransmitter changes caused by diet restriction, might have implications for the treatment of cachexia associated with acquired immunodeficiency syndrome (AIDS) and cancer, for mood changes sometimes associated with dieting, and in the extreme case, of patients with anorexia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762668     DOI: 10.1016/s0014-2999(00)00059-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  45 in total

Review 1.  Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice.

Authors:  G Kunos; S Bátkai
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine.

Authors:  Aaron N A Verty; Malini E Singh; Iain S McGregor; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2003-04-17       Impact factor: 4.530

Review 3.  The endocannabinoid system: role in energy regulation.

Authors:  Thomas F Gamage; Aron H Lichtman
Journal:  Pediatr Blood Cancer       Date:  2012-01       Impact factor: 3.167

4.  Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.

Authors:  E K Jones; T C Kirkham
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.

Authors:  Garron T Dodd; Giacomo Mancini; Beat Lutz; Simon M Luckman
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 6.  Endocannabinoids and the Endocrine System in Health and Disease.

Authors:  Cecilia J Hillard
Journal:  Handb Exp Pharmacol       Date:  2015

Review 7.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 8.  Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.

Authors:  John D Salamone; Peter J McLaughlin; Kelly Sink; Alexandros Makriyannis; Linda A Parker
Journal:  Physiol Behav       Date:  2007-04-14

9.  Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal.

Authors:  Hao Huang; Claudio Acuna-Goycolea; Ying Li; H M Cheng; Karl Obrietan; Anthony N van den Pol
Journal:  J Neurosci       Date:  2007-05-02       Impact factor: 6.167

Review 10.  Treatment studies with cannabinoids in anorexia nervosa: a systematic review.

Authors:  Emilie Vangsgaard Rosager; Christian Møller; Magnus Sjögren
Journal:  Eat Weight Disord       Date:  2020-04-02       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.